Resected EGFR-mutated non-small-cell lung cancers : incidence and outcomes in a European population (GFPC Exerpos Study)
© The Author(s), 2024..
Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations. The main objective of this study was to describe, in the real-world setting, these patients' incidence, clinical, and tumoral characteristics.
Methods: The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France. EGFR status was determined retrospectively when not available before surgery.
Results: The study includes 1391 no squamous NSCLC patients from 16 centers; EGFR status was determined before surgery in 692 (49.7%) of the cases and conducted as part of the study for 699 (50.3%); 171 (12.3%) were EGFR mutated; median age: 70 (range: 36-88) years; female: 59.6%; never smokers: 75.7%; non-squamous histology 97.7%, programmed death ligand-1 expression 0%/1-49%/⩾50 in 60.5%/25.7%/13.8%, respectively. Surgery was predominantly lobectomy (81%) or segmentectomy (14.9%), with systematic lymph node dissection in 95.9%. Resection completeness was R0 for 97%. Post-surgery staging was as follows: IA: 52%, IB: 16%, IIA: 4%, IIB: 10%, IIIA: 16%, and IIIB: 0.05%; EGFR mutation exon was Del19/exon 21 (L858R)/20/18 in 37.4%/36.8%/14%, and 6.4% of cases, respectively; 31 (18%) patients received adjuvant treatment (chemotherapy: 93%, EGFR tyrosine kinase inhibitor: 0%, radiotherapy: 20%). After a median follow-up of 31 (95% confidence interval: 29.6-33.1) months, 45 (26%) patients relapsed: 11/45 (24%) locally and 34 (76%) with metastatic progression. Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60%.
Conclusion: This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 16(2024) vom: 15., Seite 17588359241236451 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Auliac, Jean-Bernard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 09.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359241236451 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369454499 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369454499 | ||
| 003 | DE-627 | ||
| 005 | 20240309232548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359241236451 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM369454499 | ||
| 035 | |a (NLM)38455711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Auliac, Jean-Bernard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Resected EGFR-mutated non-small-cell lung cancers |b incidence and outcomes in a European population (GFPC Exerpos Study) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2024. | ||
| 520 | |a Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations. The main objective of this study was to describe, in the real-world setting, these patients' incidence, clinical, and tumoral characteristics | ||
| 520 | |a Methods: The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France. EGFR status was determined retrospectively when not available before surgery | ||
| 520 | |a Results: The study includes 1391 no squamous NSCLC patients from 16 centers; EGFR status was determined before surgery in 692 (49.7%) of the cases and conducted as part of the study for 699 (50.3%); 171 (12.3%) were EGFR mutated; median age: 70 (range: 36-88) years; female: 59.6%; never smokers: 75.7%; non-squamous histology 97.7%, programmed death ligand-1 expression 0%/1-49%/⩾50 in 60.5%/25.7%/13.8%, respectively. Surgery was predominantly lobectomy (81%) or segmentectomy (14.9%), with systematic lymph node dissection in 95.9%. Resection completeness was R0 for 97%. Post-surgery staging was as follows: IA: 52%, IB: 16%, IIA: 4%, IIB: 10%, IIIA: 16%, and IIIB: 0.05%; EGFR mutation exon was Del19/exon 21 (L858R)/20/18 in 37.4%/36.8%/14%, and 6.4% of cases, respectively; 31 (18%) patients received adjuvant treatment (chemotherapy: 93%, EGFR tyrosine kinase inhibitor: 0%, radiotherapy: 20%). After a median follow-up of 31 (95% confidence interval: 29.6-33.1) months, 45 (26%) patients relapsed: 11/45 (24%) locally and 34 (76%) with metastatic progression. Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60% | ||
| 520 | |a Conclusion: This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EGFR mutation | |
| 650 | 4 | |a lung cancer management | |
| 650 | 4 | |a surgery | |
| 700 | 1 | |a Thomas, Pascal-Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Bylicki, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Guisier, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Curcio, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a AlainVegnenègre |e verfasserin |4 aut | |
| 700 | 1 | |a Swalduz, Aurelie |e verfasserin |4 aut | |
| 700 | 1 | |a Wislez, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Le Treut, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Decroisette, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Basse, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Falchero, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a De Chabot, Gonzague |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Huchot, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Lupo Mansuet, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Blons, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Chouaïd, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Greillier, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 16(2024) vom: 15., Seite 17588359241236451 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g day:15 |g pages:17588359241236451 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359241236451 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |b 15 |h 17588359241236451 | ||